Ranger banner image

Effortless Deliverability. Exceptional Outcomes.

Ranger Drug-Coated Balloon

Ranger™️drug-coated balloon consistently delivers exceptional outcomes with effortless deliverability

Ranger™ consistently delivers exceptional outcomes with effortless deliverability

Restenosis poses a significant, prevalent challenge in superior femoral artery (SFA) management. Boston Scientific is dedicated to overcoming peripheral arterial disease (PAD) challenges with bold innovation using next-generation drug-eluting technology. Boston Scientific is the first company to voluntarily evaluate our drug-coated balloon against another drug-coated balloon (DCB) in a level-1 randomised controlled trial for comparative effectiveness.

Icon representing positive result

Consistently high 12-month primary patency demonstrated across multiple randomised controlled trials (RCT)1,2

Icon representing trial outcomes

Similar outcomes observed with low dose Ranger Drug-Coated Balloon (DCB) compared to higher dose IN.PACT2 DCB

Icon representing reduction

Significantly lower 12-month clinically driven target lesion revascularisation (CD-TLR) rate with Ranger versus uncoated percutaneous transluminal angioplasty (PTA)1

Ranger demonstrated consistently high primary patency versus uncoated PTA (RANGER II) and IN.PACT (COMPARE) at 12 months¹⁻²

Ranger patency versus PTA and IN.PACT

Ranger demonstrated similar primary patency to IN.PACT™ DCB, using around half the paclitaxel dose at 12 months²

Ranger low-dose patency versus IN.PACT

Ranger demonstrated a significantly lower 12-month CD-TLR rate versus uncoated PTA, resulting in a 67% relative reduction in repeat procedures¹

Ranger CD-TLR versus uncoated PTA


1. Sachar R et al. RANGER II SFA Investigators. 1-year results from the RANGER II SFA randomized trial of the Ranger drug-coated balloon. JACC Cardiovasc Interv. 2021;10:1123–1133.

2. Steiner S, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41:2541–2552.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.